Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors
← catalyst calendarNCT05799274 · readout ≤ 12 d
Sponsored by Radiopharm Theranostics, Ltd (industry) · RADX — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Na · None · Diagnostic
Enrollment
9estimated
Sites
2
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-11-09 | actual | When the study began enrolling |
| Primary completion | Aug 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-04-05 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Healthy Volunteers
- Pancreatic Ductal Adenocarcinoma
- Non-small Cell Lung Cancer (NSCLC)
- Esophageal Squamous Cell Carcinoma
- Cervical Cancer
- Endometrial Cancer
- Ovarian Cancer
Intervention
- Drug: RAD301 ([68Ga]-RAD301)
Primary outcomes
what the primary-completion date above is the date OFRadiation dosimetry of RAD301
measured 6 hours
Radiation dosimetry of RAD301
measured 6 hours
Safety and tolerability of RAD301
measured 4 weeks
Permalink · RADX's whole pipeline · Catalyst calendar · Every registered study · What changed